JP2017502023A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502023A5 JP2017502023A5 JP2016540993A JP2016540993A JP2017502023A5 JP 2017502023 A5 JP2017502023 A5 JP 2017502023A5 JP 2016540993 A JP2016540993 A JP 2016540993A JP 2016540993 A JP2016540993 A JP 2016540993A JP 2017502023 A5 JP2017502023 A5 JP 2017502023A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- macular degeneration
- age
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920541P | 2013-12-24 | 2013-12-24 | |
| US61/920,541 | 2013-12-24 | ||
| PCT/US2014/049938 WO2015099838A2 (en) | 2013-12-24 | 2014-08-06 | Compositions and methods of treating ocular diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017502023A JP2017502023A (ja) | 2017-01-19 |
| JP2017502023A5 true JP2017502023A5 (https=) | 2017-09-14 |
Family
ID=53479755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016540993A Pending JP2017502023A (ja) | 2013-12-24 | 2014-08-06 | 眼疾患を治療する組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10183989B2 (https=) |
| EP (1) | EP3086809A4 (https=) |
| JP (1) | JP2017502023A (https=) |
| AU (1) | AU2014370404A1 (https=) |
| CA (1) | CA2934462A1 (https=) |
| WO (1) | WO2015099838A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3489261T3 (pl) | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| WO2017152088A1 (en) | 2016-03-04 | 2017-09-08 | JN Biosciences, LLC | Antibodies to tigit |
| IL299099B2 (en) | 2016-06-27 | 2025-07-01 | Univ California | Cancer treatment combinations |
| KR102369014B1 (ko) * | 2016-08-16 | 2022-03-02 | 리제너론 파아마슈티컬스, 인크. | 혼합물로부터 개별 항체들을 정량하는 방법 |
| WO2019033081A1 (en) * | 2017-08-11 | 2019-02-14 | Massachusetts Eye And Ear Infirmary | INHIBITION OF THE SUPPLEMENTARY ALTERNA PATHWAY FOR THE TREATMENT OF RETINAL ISCHEMIC LESION AND GLAUCOMA |
| US20190247560A1 (en) | 2018-02-13 | 2019-08-15 | Gambro Lundia Ab | Extracorporeal devices and methods of treating complement factor related diseases |
| WO2019195136A1 (en) | 2018-04-03 | 2019-10-10 | Ngm Biopharmaceuticals, Inc. | C3-binding agents and methods of use thereof |
| EP3586865A1 (en) * | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis |
| CN109999015A (zh) * | 2019-04-24 | 2019-07-12 | 江苏省中医药研究院 | 紫草素在制备预防或治疗房颤药物中的用途 |
| BR112022024221A2 (pt) | 2020-06-02 | 2022-12-20 | Arcus Biosciences Inc | Anticorpos para tigit |
| AU2021356298A1 (en) * | 2020-10-07 | 2023-05-04 | Line 6 Biotechnology, Inc | Methods and agents for the treatment of ocular disease |
| US11981727B2 (en) | 2021-08-31 | 2024-05-14 | Novelmed Therapeutics, Inc | Monospecific and bispecific antibodies and antigen binding fragments thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003039404A2 (en) * | 2001-11-09 | 2003-05-15 | Eyetech Pharmaceuticals | Methods for treating ocular neovascular diseases |
| EP1931379B1 (en) * | 2005-10-07 | 2013-05-29 | Health Protection Agency | Proteins with improved solubility and methods for producing and using same |
| EP3299027A1 (en) * | 2005-11-04 | 2018-03-28 | Genentech, Inc. | Use of complement pathway inhibitors to treat ocular diseases |
| KR101584468B1 (ko) | 2006-03-08 | 2016-01-13 | 아케믹스 엘엘씨 | 안질환의 치료에 유용한 보체 결합 앱타머 및 항-ｃ5 제제 |
| US9745367B2 (en) * | 2007-03-23 | 2017-08-29 | Novelmed Theraputics, Inc. | Alternative pathway specific antibodies for treating arthritis |
| US20100015139A1 (en) * | 2008-07-10 | 2010-01-21 | Rekha Bansal | METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF |
| BRPI0812767A2 (pt) * | 2007-06-07 | 2014-12-02 | Genentech Inc | Anticorpos para c3b e métodos para prevenção e tratamento de distúrbios associados ao complemento |
| US20100291106A1 (en) * | 2009-05-06 | 2010-11-18 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c3b |
| AU2011224224B2 (en) * | 2010-03-10 | 2015-07-09 | Novelmed Therapeutics, Inc. | Humanized and chimeric anti-properdin antibodies |
| US20190202898A9 (en) * | 2012-04-03 | 2019-07-04 | Novelmed Therapeutics, Inc. | AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF |
| WO2013152020A1 (en) | 2012-04-03 | 2013-10-10 | Novelmed Therapeutics, Inc. | Humanized and chimeric anti-factor bb antibodies and uses thereof |
| US9243060B2 (en) * | 2012-04-03 | 2016-01-26 | Novelmed Therapeutics, Inc. | Humanized anti-factor C3b antibodies and uses thereof |
-
2014
- 2014-08-06 WO PCT/US2014/049938 patent/WO2015099838A2/en not_active Ceased
- 2014-08-06 CA CA2934462A patent/CA2934462A1/en not_active Abandoned
- 2014-08-06 EP EP14874978.1A patent/EP3086809A4/en not_active Withdrawn
- 2014-08-06 US US15/106,017 patent/US10183989B2/en active Active
- 2014-08-06 JP JP2016540993A patent/JP2017502023A/ja active Pending
- 2014-08-06 AU AU2014370404A patent/AU2014370404A1/en not_active Abandoned
-
2019
- 2019-01-22 US US16/254,173 patent/US10696740B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017502023A5 (https=) | ||
| EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
| EA201890305A1 (ru) | Гуманизированные или химерные cd3-антитела | |
| EA201891732A1 (ru) | Биспецифичные связывающие белки для pd-l1 и kdr | |
| EA201890453A1 (ru) | Анти-angptl8 антитела и их применение | |
| PE20240111A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
| EA201890834A1 (ru) | Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения | |
| NZ706377A (en) | Il-6 antagonists and uses thereof | |
| EA201791168A1 (ru) | Способы и составы для лечения сосудистых заболеваний глаз | |
| WO2014152006A3 (en) | Anti-hepcidin antibodies and uses thereof | |
| AR105267A1 (es) | Anticuerpos de unión a tau | |
| WO2014186622A3 (en) | Methods of treatment for guillain-barre syndrome | |
| PH12015501505B1 (en) | Antibodies that bind to tl1a and their uses | |
| WO2018165062A8 (en) | Anti-c5 antibodies and uses thereof | |
| NZ630610A (en) | Tau peptides, anti-tau antibodies, and methods of use thereof | |
| EA201591113A1 (ru) | Антитела против антигена 2 дендритных клеток крови и их применение | |
| EA201791712A1 (ru) | Антитела к транстиретину | |
| HK1208499A1 (en) | Dual receptor antagonistic antigen-binding proteins and uses thereof | |
| MX2017001959A (es) | Anticuerpos especificos para mmp9. | |
| MX366359B (es) | Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1). | |
| NZ730186A (en) | Humanized anti-hepcidin antibodies and uses thereof | |
| PH12017500699A1 (en) | Antibodies that bind to ccr6 and their uses | |
| WO2018089807A3 (en) | Anti-cd46 antibodies and methods of use | |
| WO2016057683A3 (en) | Novel anti-nodal antibodies and methods of using same | |
| WO2017079443A8 (en) | Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same |